Jupiter Neurosciences, Inc. (JUNS)
NASDAQ: JUNS · Real-Time Price · USD
0.6100
-0.0900 (-12.86%)
At close: Mar 31, 2025, 4:00 PM
0.6579
+0.0479 (7.86%)
Pre-market: Apr 1, 2025, 5:38 AM EDT
Jupiter Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
20.19M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
JUNS News
- 7 weeks ago - Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - GlobeNewsWire
- 2 months ago - Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial - GlobeNewsWire
- 4 months ago - Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering - GlobeNewsWire
- 4 months ago - Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq - GlobeNewsWire
- 2 years ago - Neuro-inflammation biotech Jupiter Neurosciences revises terms, removes warrants ahead of $15 million IPO - Renaissance Capital